Design and evaluation of dihydroisoquinolines as potent and orally bioavailable human cytomegalovirus inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 13, 2000, Pages 1477-1480

  Chan, Laval ^a   Stefanac, Tomislav ^a   Turcotte, Nathalie ^a   Hu, Zhuhan ^a   Chen, Yanmin ^a   Bédard, Jean ^a   May, Suzanne ^a   Jin, Haolun ^a  

^a Shire Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROISOQUINOLINE; ISOQUINOLINE DERIVATIVE; NAPHTHYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HUMAN CYTOMEGALOVIRUS; MONKEY; MOUSE; NONHUMAN;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CELL DIVISION; CELL LINE; CYTOMEGALOVIRUS; DRUG DESIGN; HUMANS; ISOQUINOLINES; MICE; MOLECULAR STRUCTURE; NAPHTHYRIDINES; PHENETHYLAMINES; PLAQUE ASSAY;

ANIMALIA; DNA VIRUSES; HUMAN HERPESVIRUS 5;

EID: 0034601259     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00265-1     Document Type: Article

References (19)

1. For recent reviews, see: (a) de Jong, M. D.; Galasso, G. J.; Gazzard, B.; Griffiths, P. D.; Jabs, D. A.; Kern, A. R.; Spector, S. A. Antiviral Res. 1998, 39, 141.
2. (b) de Jong, M. D.; Boucher, C. A. B.; Danner, S. A.; Gazzard, B.; Griffiths, P. D.; Katlama, C.; Lange, J. M. A.; Richman, D. D.; Vella, S. Antiviral Res. 1998, 37, 1.
3. (c) Bernstein, K. BioCentury 1996, 4, 83.
4. (d) Perry, C. M.; Davis, R. Pharmacoeconomics 1997, 12, 209.
5. Bruggeman C.A., Marjorie H.J., Nelissen-Vrancken G. Antiviral Res. 43:1999;135.
6. (a) Chan, L.; Jin, H.; Stefanac, T.; Lavallée, J.-F.; Falardeau, G.; Wang, W.; Bédard, J.; May, S.; Yuen, L. J. Med. Chem. 1999, 42, 3023.
7. (b) Chan, L.; Jin, H.; Stefanac, T.; Wang, W.; Lavallée, J.-F.; Bédard, J.; May, S. Bioorg. Med. Chem. Lett. 1999, 9, 2583.
8. Parkinson, A. In Casarett and Doull's Toxicology: The Basic Science of Poisons; 5th ed.; Klaassen, C. D., Ed.; McGraw-Hill: New York, 1995, Chapter 2.
9. Kobayashi Y., Kumada I., Sato H. Chem. Pharm. Bull. 17:1969;1045.
10. Dmowski W., Wielgat J. J. Fluorine Chem. 41:1988;241.
11. Kappe, Th.; Pfaffenschlager, A.; Stadlbauer, W. Synthesis 1989, 666.
12. Echavarren A.M., Stille J.K. J. Am. Chem. Soc. 109:1987;5478.
13. Lowe, P. A. In Comprehensive Heterocyclic Chemistry; Katritzcky A. R.; Rees, C. W., Ed.; Pergamon: Oxford; Vol. 2. pp 581-627.
14. Lardenois P., Frost J., Dargazanali G., George P. Synth. Commun. 26:1996;2305.
15. (a) Mander, L. N.; Sethi, P. Tetrahedron Lett. 1983, 24, 5425.
16. (b) Yanmato, M.; Yoshida, H.; Ikezawa, K.; Kohashi, Y. Chem. Pharm. Bull. 1986, 34, 71.
17. Bédard J., May S., L'Heureux L., Stamminger T., Copsey A., Drach J., Huffman J., Chan L., Jin H., Rando R.F. Antimicrob. Agents Chemother. 44:2000;929.
18. Falardeau, G.; Chan, L.; Stefanac, T.; May, S.; Jin, H.; Lavallée, J.-F. Manuscript in preparation.
19. 1 2) was calculated from 0.693/λz. Chen, Y.; Mongrain, I.; Richard, A.; Chan, L.; Winocour, P.; Hu, Z. Antiviral Chem. Chemother. submitted.